Besides its potential for IDH mutation typing in vivo, the HSQC sequence developed here for ex vivo samples could be applied essentially immediately in the (neuro)surgery setting to identify patients with IDH-mutant tumors as well as delineating tumor versus normal brain tissue and in the future to type for other potentially targetable metabolic vulnerabilities as they are discovered. Here, IDH2 is linked to neoplasm.